1 not yet recruiting, 1 recruiting, 1 unknown. 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 1, Unknown 1 |
| Not applicable | 1 | Not yet recruiting 1 |
Follow EGFR-TKI: new trials by email Literature Review of EGFR-TKI trials Research Report on EGFR-TKI
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs Ivonescimab combined with chemotherapy - NSCLC, Chemotherapy | Not applicable | Not yet recruiting | Jiangsu Province Nanjing Brain Hospital | 36 | 2025-01-01 | 2025-01-09 |
| Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia Timolol 0.5% eye drops and betamethasone valerate 0.1% cream, Betamethasone valerate 0.1% cream - Paronychia, EGFR-TKI | Phase 3 | Recruiting | Queen Mary Hospital, Hong Kong | 40 | 2024-10-09 | 2024-10-18 |
| Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC Apatinib（Tab. 500mg/d） combined with EGFR-TKI（as previously） - NSCLC, Apatinib | Phase 3 | Unknown | Shenzhen People's Hospital | 54 | 2017-12-01 | 2019-04-04 |
Meningeal Carcinomatosis (1) · Paronychia (1)
Central Nervous System Neoplasms (1) · Infections (1) · Meningeal Neoplasms (1) · Nail Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1) · Skin Diseases (1) · Skin Diseases, Infectious (1) · Skin and Connective Tissue Diseases (1)
Betamethasone Valerate (1) · Drug Therapy (1) · Ophthalmic Solutions (1) · Timolol (1)
Jiangsu Province Nanjing Brain Hospital (1) · Queen Mary Hospital, Hong Kong (1) · Shenzhen People's Hospital (1)
China (1) · Hong Kong (1)
PMID 25601652, PMID 37879536, PMID 38642937, PMID 38820549, PMID 39073550, PMID 39661345, PMID 39661367, PMID 39661384